Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 09, 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021. Bipolar depression...
Intra-Cellular Therapies to Host Third Quarter 2021 Financial Results Conference Call and Webcast
November 02, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Amended Start Time to Virtual Event on Wednesday, October 20
October 18, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
Webcast to begin at 1:00 p.m. ET Virtual event to include discussions on our lumateperone, ITI-1284, PDE1 inhibitors, and ITI-333 platforms NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) --...
Intra-Cellular Therapies to Host a Virtual Event to Feature Highlights of Several of its Development Programs
October 08, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
Virtual event to include discussions on our lumateperone, ITI-1284, PDE1 inhibitors and ITI-333 platforms Webcast scheduled for Wednesday, Oct. 20 from 12:30 to 3:30 p.m. ET NEW YORK, Oct. 08, 2021...
Intra-Cellular Therapies Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry
September 27, 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
In this study, lumateperone 42 mg showed significant reduction in depressive symptoms compared to placebo in patients with a major depressive episode associated with bipolar I or bipolar II disorder...
Intra-Cellular Therapies to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Publications Highlighting Beneficial Effects of Phosphodiesterase Type I Inhibition with Lenrispodun (ITI-214) on Cardiovascular Function in Patients with Heart Failure and in Models of Accelerated Aging
September 20, 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
Results of Study ITI-214-104 show that lenrispodun, in a Phase 1/2a Study, is well tolerated and acts as an inodilator in patients with heart failure without inducing abnormal heart rhythms...
Intra-Cellular Therapies to Present at the Canaccord Genuity 41st Annual Growth Conference
August 10, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 09, 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021. Second quarter CAPLYTA...
Intra-Cellular Therapies to Host Second Quarter 2021 Financial Results Conference Call and Webcast
August 02, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...